GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Thrombogenics Outlicenses Stem Cell Medium Technology to Millipore

  • ThromboGenics will exclusively license its technology to Millipore for the company to produce its stem cell culture medium, RESGRO™.

     

    Under this global license agreement agreement, ThromboGenics will license to Millipore its patents, data, and know-how for the manufacturing, development, and evaluation of RESGRO. Millipore will assume responsibility for the exclusive production and sales of the medium as well as all future costs. ThromboGenics will receive upfront and milestone payments and will earn double digit royalties on Millipore's sales.


    The technology for producing RESGRO was originally developed by the ThromboGenics drug discovery team as part of its efforts to identify several of its drug discovery candidates currently in clinical trials.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?